ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Among the 20 myeloid and lymphoid markers analyzed, higher expression levels of CD7 and CD36 were observed in CML-BP compared with BCR::ABL1 negative AML (36% vs 6%, p = 0.0059 and 41% vs 11%, p = 0.0014, respectively; Fig. 2B, C).